Ocular Manifestations of Scleroderma

Survey of Ophthalmology

Volumn 54, Issue 2, 2009, Pages 292-304

  Tailor, Rajen ^a   Gupta, Abha ^b   Herrick, Ariane ^c   Kwartz, Jeffrey ^d  

^a CITY HOSPITAL   (United Kingdom)

^b CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

pathogenesis; scleroderma; systemic sclerosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; CONNECTIVE TISSUE GROWTH FACTOR; DIMETHYL SULFOXIDE; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; FIBRILLARIN; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; THORIUM; TRANSCRIPTION FACTOR TAL1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BLEPHAROPHIMOSIS; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTROMERE; CLINICAL FEATURE; ENDOPHTHALMITIS; EYE INFLAMMATION; FIBROSIS; GLAUCOMA; HUMAN; IMMUNE SYSTEM; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LAGOPHTHALMOS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VASCULAR DISEASE;

EYE DISEASES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 61949389257     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2008.12.007     Document Type: Article

References (96)

1. Agatson H.J. Scleroderma with retinopathy. Am J Ophthalmol 36 (1953) 120-121
2. Alarcon-Segovia D., Ibanez G., Hermandez-Ortiz J., et al. Sjogren's syndrome in progressive systemic sclerosis (scleroderma). Am J Med 57 (1974) 78-85
3. Al-Husainy D.J. Bilateral keratomalacia in a cachectic scleroderma patient. Eye 13 (1999) 586-588
4. Allanore Y., Parc C., Monnet D., et al. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis 63 (2004) 1276-1278
5. Allanore Y., Kahan A., and Brezin A. Authors' reply. Ann Rheum Dis 64 (2005) 341-344
6. Arnett F.C., and Michels R.G. Inflammatory ocular myopathy in systemic sclerosis (scleroderma). A case report and review of the literature. Arch Intern Med 132 5 (1973) 740-743
7. Ashton N., Coomes E.N., Garner A., and Oliver D.O. Retinopathy due to progressive systemic sclerosis. J Path 96 (1968) 259-268
8. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
9. Boin-Francesco R.A. Autoimmunity in systemic sclerosis: current concepts. Curr-Rheumatol-Rep 9 (2007) 165-172
10. Boschi A., Snyers B., and Lambert M. Bilateral optic neuropathy associated with the crest variant of scleroderma. Eur J Ophthalmol 3 (1993) 219-222
11. Campbell P.M., and LeRoy E.C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum 4 (1975) 351-368
12. Chan A.Y.K., and Liu D.T.L. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis 64 (2005) 341-344
13. Cullen J.F., and Coleiro J.A. Ophthalmic complications of giant cell arteritis. Surv Ophthalmol 20 (1976) 247-258
14. Di Rosa F., and Barnaba V. Persisting viruses and chronic inflammation: understanding their relation to autoimmunity. Immunol Rev 164 (1998) 17-27
15. Duke-Elder S., and Dobree J.H. Diseases of the retina, in Duke-Elder vol. X (1967), System of Ophthalmology, London, Kimpton 511-512
16. Duncan M.R., and Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97 (1991) 686-692
17. Farkas T.G., Sylvester V., and Archer D. The choroidopathy of progressive systemic sclerosis. Am J Ophthalmol 74 (1972) 875-886
18. Ferry A.P., Font R.L., Weinberg R.S., et al. Nocardial endophthalmitis: report of two cases studied histopathologically. Br J Ophthalmol 72 (1988) 55-61
19. Fox R. Sjogren's syndrome. Lancet 366 (2005) 321-331
20. Gharaee-Kermani M., Denholm E.M., and Phan S.H. Co-stimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol Chem 271 (1996) 17779-17784
21. Gilliland B.C. Systemic sclerosis (scleroderma). In: Braunwald E., Fauci A., and Kasper D. (Eds). Harrison's Internal Medicine. 16th ed (2005), McGraw Hill, New York 1979-1989
22. Grennan D.M., and Forrester J. Involvement of the eye in SLE and scleroderma. A study using fluorescein angiography in addition to clinical ophthalmic assessment. Ann Rheum Dis 36 (1977) 152-156
23. Haseqawa M., Fujimoto M., Takehara K., and Sato J. Pathogenesis of systemic sclerosis: Altered B-cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39 (2005) 1-7
24. Hénault J., Robitaille G., Senécal J.L., and Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54 (2006) 963-973
25. Hesse R.J., and Slagle D.F. Scleroderma choroidopathy: report of an unusual case. Ann Ophthalmol 14 (1982) 524-525
26. Horan E.C. Ophthalmic manifestations of progressive systemic sclerosis. Br J Ophthalmol 53 (1969) 388-392
27. Horie K., Nishi M., Sawa M., and Mochizuki M. A case of peripheral corneal ulcer accompanied by progressive systemic sclerosis. Acta Soc Ophthalmol Jpn 96 (1992) 922-929
28. Hupp S.L. Giant cell arteritis associated with progressive systemic sclerosis. J Clin Neuroophthalmol 9 (1989) 126-130
29. Kagami S., Border W.A., Miller D.E., and Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor -B expression in rat glomerular mesangial cells. J Clin Invest 93 (1994) 2431-2437
30. Kalogirou A., Gelou E., Mountantonakis S., et al. Early T-cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64 (2005) 1233-1235
31. Kanski J.J. Clinical Ophthalmology: Systematic Approach. ed 3 (1994), Butterworth/Heinemann, Oxford
32. Kawaguchi Y., TaKagi K., Hara M., et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type I receptors. Arthritis Rheum 50 (2004) 216-226
33. Kirkham T.H. Scleroderma and Sjogren's syndrome. Br J Ophthalmol 53 (1969) 131-133
34. Kovacs E.J. Fibrinogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 12 (1991) 17-23
35. Kovacs E.J., and DiPietro L.A. Fibrogenic cytokines and connective tissue production. FASEB J 8 (1994) 854-861
36. Kraus A., Guerra-Bautista G., Espinoza G., et al. Defects on the retinal pigment epithelium in scleroderma. Br J Rheumatol 30 (1991) 112-114
37. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (1988) 202-205
38. Littlejohn G., Urowitz M., and Pavlin C. Central retinal vein occlusion and scleroderma: implications for sclerodermatous vascular disease. Ann Rheum Dis 40 (1981) 96-99
39. Lunardi C., Bason C., Navone R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6 (2000) 1183-1186
40. Mabon M., Whitcher J.P., and Anderson R. Bilateral scleral pits associated with systemic sclerosis. Am J Ophthalmol 128 (1999) 521-522
41. MacLean H., and Guthrie W. Retinopathy in scleroderma. J Am Oph Soc 89 (1969) 209-212
42. Mancel E., Janin A., Gosset D., et al. Conjunctival biopsy in scleroderma and primary Sjogren's syndrome. Am J Ophthalmol 115 (1993) 729-9
43. Mayes M.D., Lacey V., Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48 (2003) 2246-2255
44. Mejias E. Superior oblique muscle paralysis in the CREST syndrome. PR Health Sci J 5 (1986) 19-27
45. Nabel E.G., Shum L., and Pompili V.J. Direct transfer of transforming growth factor B1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90 (1993) 10759-10763
46. Nguyen V.A., Sgonc R., Dietrich H., and Wick G. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (scleroderma). J Autoimmun 14 (2000) 143-149
47. Nielsen N.V. The normal fundus fluorescein angiogram and the normal fundus photograph. Acta Ophthal Suppl 180 (1986) 1-30
48. Nishijima C., Hayakawa I., Matsushita T., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138 (2004) 357-363
49. Oliver J.A., and Cannon P.J. The kidney in scleroderma. Nephron 18 (1977) 141-150
50. Olver J., and Laidler P. Acquired Brown's syndrome in a patient with combined lichen sclerosus et atrophicus and morphoea. Br J Ophthalmol 72 (1988) 552-557
51. Ong C., Wong C., Roberts C.R., et al. Anti IL-4 treatment prevents dermal collagen deposition in the tight skin mouse model of scleroderma. Eur J Immunol 28 (1998) 2619-2629
52. Page C., Rose M., Yacoub M., and Pigott R. Antigenic heterogeneity of vascular endothelium. Am J Pathol 141 (1992) 673-683
53. Pandey J.P., and LeRoy E.C. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection, and coronary restenosis. Arthritis Rheum 41 (1998) 10-15
54. Peter S., Dietrich H., and Wick G. Investigations for retinopathy in an avian model for systemic sclerosis. Exp Eye Res 79 (2004) 85-92
55. Prescott R.J., Freemont A.J., Jones C.J.P., et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166 (1992) 255-263
56. Proctor B., Chang T., and Hay D. Parafoveal telangiectasia in association with CREST syndrome. Arch Ophthalmol 16 (1998) 814-815
57. Ramboer K., Demaerel P., Baert A.L., et al. Linear scleroderma with orbital involvement: follow up and magnetic resonance imaging. Br J Ophthalmol 81 (1997) 90-91
58. Rincon M., Anguita J., Nakamura T., et al. Interleukin (IL) 6 directs the differentiation of IL-4 producing CD4 + T-cells. J Exp Med 185 (1997) 461-469
59. Romano C., Barrett D.A., Li Z., et al. Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest Ophthalmol Vis Sci 36 (1995) 1968-1975
60. Ruprecht K.W., Naumann G.O.H., and Apple D.J. Auge und Allgemeinkrankheimten. In: Naumann G.O.H., and Apple D.J. (Eds). Pathologie des Auges (1997), Springer, Heidelberg 1451-1546
61. Rush J.A. Isolated superior oblique paralysis in progressive systemic sclerosis. Ann Ophthalmol. Ann Ophthalmol 13 (1981) 217-220
62. Saari K.M., Rudenberg H.A., and Laitinen O. Bilateral central retinal vein occlusion in a patient with scleroderma. Ophthalmologica 182 (1981) 7-12
63. Sakkas L.I. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 38 (2005) 113-116
64. Sakkas L.I., and Platsoucas C.D. Is systemic sclerosis an antigen driven T-cell disease?. Arthritis Rheum 50 (2005) 1721-1733
65. Sato S., Hasegawa M., Fujimoto M., et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165 (2000) 6635-6643
66. Serup L., Serup J., and Hagdrup H.K. Increased central cornea thickness in systemic sclerosis. Acta Ophthalmol 62 (1984) 69-74
67. Serup L., Serup J., and Hagdrup H. Fundus fluorescein angiography in generalized scleroderma. Ophthalmic Res 19 (1987) 303-308
68. Sgonc R., Gruschwitz M.S., Dietrich H., et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98 (1996) 785-792
69. Sgonc R., Gruschwitz M.S., Boeck G., et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43 (2000) 2550-2562
70. Shimohata T., Sato T., Akaiwa Y., et al. Isolated trochlear nerve palsy in CREST syndrome. Eur Neurol 50 (2003) 181-182
71. Shirley H.H., Lendergan M.K., William H.J., and Spruance S.L. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma. Pharmacotherapy 9 (1989) 165-168
72. Shi-Wen X., Pennington D., Holmes A., et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrous genes in systemic sclerosis. Exp Cell Res 259 (2000) 213-244
73. Shi-Wen X., Denton C.P., Dashwood M.R., et al. Fibroblast matrix gene expression and connective tissue remodelling: Role of endothelin-1. J Invest Dermatol 116 (2001) 417-425
74. Sii F., Lee G.A., Snfilippo P., and Stephensen D.C. Pellucid marginal degeneration and scleroderma. Clin Exp Optom 87 (2004) 180-184
75. Steigerwald J.C. Renal involvement in systemic sclerosis (scleroderma). In: Jayson M.I.V., and Black C.M. (Eds). Systemic Sclerosis: Scleroderma (1988), Wiley, New York 221-239
76. Stucchi C.A., and Geiser J.D. Manifestations oculars de la scleroderme generalisee. Doc Ophthalmol 22 (1967) 72-111
77. Subcommittee for Scleroderma. Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23 (1980) 581-590
78. Tedder T.F., Inaoki M., and Sato S. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6 (1997) 107-118
79. Tezel G., Edward D.P., and Wax M.B. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthalmol 117 (1999) 917-924
80. Tezel G., Seigel G.M., and Wax M.B. Autoantibodies to small heat shock proteins in glaucoma. Invest Ophthalmol Vis Sci 39 (1998) 2277-2287
81. Tezel G., and Wax M.B. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J Neurosci 20 (2000) 3552-3562
82. Usiyama O., Ushiyama K., Yamada T., et al. Retinal findings in systemic sclerosis: a comparison with nailfold capillaroscopic patterns. Ann Rheum Dis 62 (2003) 204-207
83. Vancheeswaran R., Azam A., Black C., and Dashwood M.R. Localisation of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 21 (1994) 1268-1276
84. Walsh F.B., and Hoyt W.F. Clinical Neuro-Ophthalmology (1969), Williams and Wilkins, Baltimore, MD pp 1175
85. Wax M., Yang J., and Tezel G. Autoantibodies in glaucoma. Curr Eye Res 25 (2002) 113-116
86. Wax M.B., Yang J., and Tezel G. Serum autoantibodies in patients with glaucoma. J Glaucoma 10 (2001) S22-S24
87. Wax M.B., Barrett D.A., and Pestronk A. Increased incidence of paraproteinemia and autoantibodies in patients with normal-pressure glaucoma. Am J Ophthalmol 117 (1994) 561-568
88. Wax M.B., Tezel G., and Edward P.D. Clinical and ocular histopathological findings in a patient with normal-pressure glaucoma. Arch Ophthalmol 116 (1998) 993-1001
89. Wax M.B., Tezel G., Saito I., et al. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol 125 (1998) 145-157
90. West R.H., and Barnett A.J. Ocular involvement in scleroderma. Br J Ophthalmol 63 (1979) 845-847
91. Whitefield M.L., Finlay D.R., Murray J.I., et al. Systemic and cell cycle specific gene expression patterns in scleroderma patients. Proc Natl Acad Sci USA 100 (2003) 12319-12334
92. Worda M., Sgonc R., and Dietrich H. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 48 (2003) 2605-2614
93. Wucherpfennig K.W., and Strominger J.L. Molecular mimicry in T-cell-mediated autoimmunity: viral peptides activate human T-cell clones specific for myelin basic protein. Cell 80 (1995) 695-705
94. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4 (2004) 583-594
95. Yamamoto T., Maeda M., Sawada A., et al. Prevalence of normal-tension glaucoma and primary open-angle glaucoma in patients with collagen diseases. Jpn J Ophthalmol 43 (1999) 539-542
96. Zhou X., Tan F.K., Milewicz D.M., et al. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the "scleroderma phenotype. J Immunol 175 (2005) 4555-4560